New hope for kids with rare muscle disease: rozanolixizumab safety trial expands

NCT ID NCT06540144

ENROLLING_BY_INVITATION Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study looks at the long-term safety of a drug called rozanolixizumab in children aged 2 and older with generalized myasthenia gravis, a condition that causes muscle weakness. The drug is given in 6-week treatment cycles. The main goal is to track serious side effects and see how well children tolerate the treatment over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS

Contacts and locations

Locations

Mg0008 20081

Taipei, Taiwan
Mg0008 20095

Taipei, Taiwan
Mg0008 20339

Ōbu, Japan
Mg0008 20340

Fuchu-shi, Japan
Mg0008 20343

Sagamihara, Japan
Mg0008 40144

Milan, Italy
Mg0008 40155

Warsaw, Poland
Mg0008 40290

Bologna, Italy
Mg0008 40733

Naples, Italy
Mg0008 40734

Lodz, Poland
Mg0008 40841

Yenimahalle, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.